ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0914

Preclinical Expansion of Autoreactive Naive B cells Drives RA onset in ACPA+ individuals

Xiaohao Wu1, Mengrui Zhang2, Orr Sharpe3, V. Michael Holers4, Jane Buckner5, Gary Firestein5, Eddie James6, Kevin Deane7 and William H. Robinson8, 1Stanford Uniersity, Stanford, 2Stanford University, Stanford, CA, 3Stanford University, Stanford, 4University of Colorado Anschutz Medical Campus, Aurora, 5Benaroya Research Institute, Seattle, 6Benaroya Research Institute, Benaroya Research Institute, 7University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 8Stanford University, Palo Alto, CA

Meeting: ACR Convergence 2025

Keywords: Anti-citrullinated Protein Autoantibodies (ACPAs), autoimmune diseases, B-Cell Targets, B-Lymphocyte, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (0897–0915) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: The cellular and molecular mechanisms underlying the progression from anti-citrullinated protein antibody (ACPA) positivity to clinical rheumatoid arthritis (RA) remain poorly understood. Defining these early immunologic events is essential for identifying predictive biomarkers and developing preventive strategies.

Methods: We conducted longitudinal single-cell profiling of peripheral blood mononuclear cells (PBMCs) collected at two timepoints: a preclinical baseline and a follow-up approximately one year later. Participants were classified into three groups: (1) ACPA⁺ converters who were ACPA-positive at baseline and developed clinical RA at follow-up; (2) ACPA⁺ non-converters who did not develop clinical RA; and (3) healthy controls who were ACPA-negative and RA-free at both timepoints. B cells were isolated and analyzed using an integrated multi-modal single-cell approach, including 5′ scRNA-seq, VDJ-seq, and CITE-seq.

Results: Single-cell analysis revealed a marked preclinical expansion of IGHM⁺ IGHD⁺ CXCR5⁺ CD69⁺ activated naïve (aNAV) B cells in ACPA⁺ converters. These aNAV cells exhibited a distinct pro-inflammatory transcriptional profile, characterized by upregulation of genes involved in immune activation, antigen presentation, impaired tolerance, and cellular stress, compared to non-converters and healthy controls. VDJ repertoire analysis revealed that within converters, IgM-expressing aNAV cells dominated the BCR landscape and exhibited elevated clonal diversity along with distinct V–J gene rearrangements across both heavy and light chains. Recombinant monoclonal antibodies derived from these IgM⁺ aNAV cells demonstrated broad autoreactivity to multiple RA-associated autoantigens, including both native and citrullinated epitopes. In contrast, aNAV cells from non-converters more closely resembled those of healthy controls in their transcriptional profiles, BCR repertoires, and autoreactivity patterns.

Conclusion: These findings identify a preclinical expansion of IGHM⁺ IGHD⁺ CXCR5⁺ CD69⁺ naïve B cells in ACPA⁺individuals who progress to RA. These cells are transcriptionally stressed, pro-inflammatory, and resistant to immune tolerance. Their BCR repertoire is enriched for diverse, autoreactive IgM antibodies with distinct V–J rearrangements. This autoreactive IgM pool may contribute to early immunologic activation and the eventual onset of rheumatoid arthritis.


Disclosures: X. Wu: None; M. Zhang: None; O. Sharpe: None; V. Holers: Q32 Bio, 12,, 2; J. Buckner: None; G. Firestein: None; E. James: None; K. Deane: Inova Diagnostics, 1; W. Robinson: None.

To cite this abstract in AMA style:

Wu X, Zhang M, Sharpe O, Holers V, Buckner J, Firestein G, James E, Deane K, Robinson W. Preclinical Expansion of Autoreactive Naive B cells Drives RA onset in ACPA+ individuals [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/preclinical-expansion-of-autoreactive-naive-b-cells-drives-ra-onset-in-acpa-individuals/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/preclinical-expansion-of-autoreactive-naive-b-cells-drives-ra-onset-in-acpa-individuals/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology